SHARE Magazine


2019 | 2018 | 2017


2019 SHARE Magazine
 


Index

 Message from the CEO
 Oral semaglutide filed in the US and EU
The day I fired my doctor
Safely in the Rainbow
Shaped tablet key to oral delivery of insulin
Novo Nordisk addresses affordable insulin
Accelerating growth in Latin America
Highlights from the first three months of 2019

 


2018 SHARE Magazine
 


Index

 Letter from the CEO, Lars Fruergaard Jørgensen
 Highlights from the first nine months of 2018
 Tresiba® revitalised with new ‘Hypos matter’ 
Novo Nordisk research centre opens in oxford
Connected insulin pens poised for launch

 


Index

 Letter from the CEO, Lars Fruergaard Jørgensen
 Highlights from the first six months of 2018
Oral semaglutide shows promising results
Ozempic® heading for the European market
Novo Nordisk focuses on treating obesity
Red Cross and Novo Nordisk enters partnership


Index

 Letter from the CEO, Lars Fruergaard Jørgensen
Highlights from the first three months of 2018
Oral semaglutide shows promising results
Ozempic® approved in the EU and Japan
First phase 3a trial with oral semaglutide completed
Updated Tresiba® label approved in the USA
How Novo Nordisk’s products in Cuba

 


2017 SHARE Magazine
 


Q3 2017

SHARE Magazine UK | SHARE Magazine DK
 

Index

 Letter from the CEO, Lars Fruergaard Jørgensen
 Highlights from the first nine months of 2017
 Camilla Sylvest joins executive management
 SUSTAIN 7: Semaglutide compared to dulaglutide
 Victoza®
 CV label approved inin the US and the EU
 Fiasp®
 a fast-acting insulin approved in the US
 Ambitious global goal: To prevent 100 million new cases of diabetes by 2045


Q2 2017

SHARE Magazine UK | SHARE Magazine DK
 

Index

 Letter from the CEO, Lars Fruergaard Jørgensen
 Highlights from the first six months of 2017
 Label update for Tresiba®
 submitted in the US
 A step closer towards a CV indication for Victoza®
   Phase 2 obesity data for semaglutide
 New data on Xultophy®
 
 Why Novo Nordisk is helping refugees


Q1 2017

SHARE Magazine UK | SHARE Magazine DK
 

Index

 Letter from the CEO, Lars Fruergaard Jørgensen
 Highlights from the first three months of 2017
 Doug Langa new head of North America Operations
 Fiasp®
 launched in Canada and EU markets
 New research centre in Oxford
 CHMP endorses Refixia®
 
 World Diabetes Foundation 15
th anniversary


Older investor materials

Investors download centre | Annual reports archive

 


Reporting on corporate responsibility
 

Finance & corporate governance

We want to be in business for the long run and deliver competitive financial returns for our shareholders in a responsible way.

About finance and corporate governance

 

Environmental responsibility

Reducing our environmental impact is both our corporate responsibility and a way to mitigate long-term risks. 

About our environmental responsibility

 

Access and affordability in diabetes

As the world’s biggest producer of medicines for diabetes, we stand on the frontline of the challenge of affordable and available insulin. 

All people diagnosed with diabetes should receive treatment